Pension Fund v. Watson Pharmaceutica

CourtCourt of Appeals for the Ninth Circuit
DecidedAugust 15, 2007
Docket04-56791
StatusPublished

This text of Pension Fund v. Watson Pharmaceutica (Pension Fund v. Watson Pharmaceutica) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pension Fund v. Watson Pharmaceutica, (9th Cir. 2007).

Opinion

FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT

EMPLOYERS-TEAMSTERS LOCAL NOS.  175 & 505 PENSION TRUST FUND, INTERNATIONAL UNION OF OPERATING ENGINEERS, LOCAL 132 PENSION PLAN, and WEST VIRGINIA LABORERS’ PENSION TRUST FUND, No. 04-56791 Pension-Fund Plaintiffs- D.C. Nos. Appellants, CV-03-08236-AHM v.  CV-03-08946-AHM CV-03-09291-AHM ANCHOR CAPITAL ADVISORS, CV-03-09628-AHM Lead Plaintiff-Appellee, OPINION and WATSON PHARMACEUTICALS, INC., ALLEN CHAO, JOSEPH C. PAPA, FRED WILKINSEN, and MICHAEL E. BOXER, Defendants-Appellees.  Appeal from the United States District Court for the Central District of California A. Howard Matz, District Judge, Presiding

Argued and Submitted November 17, 2006—Pasadena, California

Filed August 16, 2007

Before: Thomas G. Nelson and Jay S. Bybee, Circuit Judges, and Kevin Thomas Duffy,* District Judge.

*The Honorable Kevin Thomas Duffy, Senior Judge, United States District Court for the Southern District of New York, sitting by designa- tion.

9973 9974 EMPLOYERS-TEAMSTERS v. WATSON PHARMACEUTICALS Opinion by Judge Duffy EMPLOYERS-TEAMSTERS v. WATSON PHARMACEUTICALS 9975

COUNSEL

Joseph D. Daley, Esq., William S. Lerach, Esq., Darren J. Robbins, Esq., Eric Alan Isaacson, Esq., Daniel S. Drosman, Esq., Lerach Coughlin Stoia Geller Rudman & Robbins LLP, for appellant Pension Fund.

Christopher Kim, Esq., Lisa J. Yang, Esq., Lim Ruger and Kim, for lead plaintiff-appellee Anchor Capital Advisors. 9976 EMPLOYERS-TEAMSTERS v. WATSON PHARMACEUTICALS Sean M. Handler, Esq., Stuart L. Berman, Esq., Robin Win- chester, Esq., Schiffrin & Barroway, LLP, for lead plaintiff- appellee Anchor Capital Advisors.

Seth Aronson, Esq., Robert C. Vanderet, Esq., David I. Hur- witz, Esq., J. Cacilia Kim, Esq., O’Melveny & Myers LLP, for defendants-appellees Watson Pharmaceuticals, Inc., Allen Chao, Joseph C. Papa, Fred Wilkinson, and Michael E. Boxer.

OPINION

DUFFY, District Judge:

Appellants, non-parties to the action below, bring this appeal from the district court’s order granting lead plaintiff’s motion to dismiss its claims in an uncertified securities class action. Because Appellants never filed a complaint or for- mally moved to intervene, they lack standing and we are therefore precluded from reaching the merits of Appellants’ argument that they would have been the proper lead plaintiff pursuant to the Private Securities Litigation Reform Act (the “PSLRA”), 15 U.S.C. § 78u-4(a). Furthermore, lead plain- tiff’s voluntary dismissal of its claims prior to class certifica- tion renders this appeal of the interim lead plaintiff order moot. Appellants’ argument that they could not file their own complaint due to the proscription against “piggybacking” on an original class action is also without merit. The appeal is dismissed.

I. Facts

On November 12, 2003, Anchor Capital Advisors (“Anchor Capital”) filed the first of four purported class actions in the Central District of California against Watson Pharmaceuti- cals, Inc. (“Watson Pharmaceuticals”) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of EMPLOYERS-TEAMSTERS v. WATSON PHARMACEUTICALS 9977 1934. Appellants did not file a complaint or move to intervene in any of the four district court actions. On February 9, 2004, the district court consolidated the four actions and considered the motions of various parties, including Appellants’, for appointment of lead plaintiff pursuant to the PSLRA. The dis- trict court preliminarily declared Anchor Capital as the lead plaintiff based upon its loss of $3.2 million on behalf of its investors, holding that it had sufficient authority to sue on behalf of its clients and that it was the party with the largest financial stake in the outcome of the litigation.1

Watson Pharmaceuticals moved to dismiss the complaint for failure to plead fraud with the particularity required by Fed.R.Civ.P. 9(b) and the PSLRA. On August 2, 2004, the district court dismissed the complaint for failure to adequately plead falsity and scienter. The order allowed Anchor Capital the opportunity to re-plead, however, held that it would be “unlikely that Plaintiffs will be able to amend to allege addi- tional facts that will satisfy the heightened pleading require- ments.” See Order Granting Motion to Dismiss the Consolidated Complaint, August 2, 2004, at 27. In light of this ruling, Anchor Capital informed the district court that it would not file another amended complaint, instead requesting that the individual uncertified actions be dismissed with preju- dice. Appellants did not object to the dismissal or take any 1 Appellants argue that an investment advisor such as Anchor Capital cannot be the appropriate lead plaintiff because it did not have express written authority to sue on its clients’ behalf, a requirement articulated by some—but not all—of the district courts that have weighed in on this issue. See, e.g., Kaplan v. Gelfond, 240 F.R.D. 88 (S.D.N.Y. 2007); Smith v. Suprema Specialties, Inc., 206 F. Supp. 2d 627, 634-35 (D.N.J. 2002). On the other hand, as the district court found here, other courts have found that an investment advisor has an interest in its own right to receive full and fair disclosures regarding the true value of a company’s stock, and therefore is a “purchaser” under the PSLRA with proper standing to pur- sue litigation on behalf of its individual clients. See, e.g., Lehocky v. Tidel Technologies, Inc., 220 F.R.D. 491, 501 (S.D. Tex. 2004); In re Rent-Way Litig., 218 F.R.D. 101, 109 (W.D. Pa. 2003). 9978 EMPLOYERS-TEAMSTERS v. WATSON PHARMACEUTICALS other action at that time. Accordingly, on September 2, 2004, the district court dismissed the action with prejudice. On appeal, Appellants now challenge the lead plaintiff ruling.

II. Discussion

a. Standing

[1] Standing is the threshold issue of any federal action, a matter of jurisdiction because “the core component of stand- ing is an essential and unchanging part of the case-or- controversy requirement of Article III.” See Lujan v. Defend- ers of Wildlife, 504 U.S. 555, 561 (1992). In this case, because the class was never certified, Appellants were not parties to the district court action and lack standing to bring this appeal. Appellants were merely potential class members in a potential class action suit. Despite ample opportunity to do so, Appellants never filed a complaint, moved to intervene, objected to the requested dismissal, or filed an amended com- plaint after Anchor Capital notified the district court that it would voluntarily dismiss its action. As articulated in Marino v. Ortiz “only parties to a lawsuit, or those that properly become parties, may appeal an adverse judgment.” Marino v. Ortiz, 484 U.S. 301, 304 (1988).

Notwithstanding this principle, the main thrust of Appel- lant’s argument is premised on Z-Seven Fund, which holds that a class member must await final judgment before it is permitted to appeal from a lead-plaintiff ruling. See Z-Seven Fund v. Motorcar Parts & Accessories, 231 F.3d 1215, 1218- 19 (9th Cir. 2000). Appellants attempt to stretch the holding of Z-Seven to imply that even putative members of a non- certified class have standing to appeal a lead-plaintiff ruling after judgment of dismissal has been entered. In light of Marino, this cannot be the case.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

American Pipe & Construction Co. v. Utah
414 U.S. 538 (Supreme Court, 1974)
Crown, Cork & Seal Co. v. Parker
462 U.S. 345 (Supreme Court, 1983)
Marino v. Ortiz
484 U.S. 301 (Supreme Court, 1988)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Devlin v. Scardelletti
536 U.S. 1 (Supreme Court, 2002)
Korwek v. Hunt
827 F.2d 874 (Second Circuit, 1987)
Smith v. Suprema Specialties, Inc.
206 F. Supp. 2d 627 (D. New Jersey, 2002)
Griffin v. PaineWebber Inc.
84 F. Supp. 2d 508 (S.D. New York, 2000)
In re Lucent Technologies, Inc., Securities Litigation
194 F.R.D. 137 (D. New Jersey, 2000)
In re Rent-Way Securities Litigation
218 F.R.D. 101 (W.D. Pennsylvania, 2003)
Lehocky v. Tidel Technologies, Inc.
220 F.R.D. 491 (S.D. Texas, 2004)
Kaplan v. Gelfond
240 F.R.D. 88 (S.D. New York, 2007)
Robbin v. Fluor Corp.
835 F.2d 213 (Ninth Circuit, 1987)
Ravens v. Iftikar
174 F.R.D. 651 (N.D. California, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Pension Fund v. Watson Pharmaceutica, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pension-fund-v-watson-pharmaceutica-ca9-2007.